SCHEMBL3089925

SCHEMBL3089925

CCOC(=O)CCNC(=O)c1ccc(NC(c2cc(-c3ccccc3)oc2C)C2CCC(O)CC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
GCG P01275 1/20 0.38
ALDH1A1 P00352 5/20 0.37
HPGD P15428 3/20 0.37
MAPT P10636 3/20 0.37
ADCY6 O43306 2/20 0.37
ADCY3 O60266 2/20 0.37
ADCY9 O60503 2/20 0.37
ADCY5 O95622 2/20 0.37
ADCY8 P40145 2/20 0.37
GCGR P47871 2/20 0.37
ADCY7 P51828 2/20 0.37
ADCY2 Q08462 2/20 0.37
ADCY1 Q08828 2/20 0.37
ADCY4 Q8NFM4 2/20 0.37
CYP1A2 P05177 3/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093610 0.91 MEN1 (0.40) MEN1KMT2AL3MBTL1GCGALDH1A1
SCHEMBL3102044 0.91 GCG (0.41) MEN1KMT2AL3MBTL1GCGALDH1A1
SCHEMBL3099625 0.89 MEN1 (0.38) MEN1KMT2AL3MBTL1GCGALDH1A1
SCHEMBL3107473 0.86 MEN1 (0.37) MEN1KMT2AL3MBTL1GCGALDH1A1
SCHEMBL3106711 0.84 GCG (0.46) GCGADCY6ADCY3ADCY9ADCY5
SCHEMBL3094745 0.84 GCG (0.45) MEN1KMT2AL3MBTL1GCGALDH1A1
SCHEMBL3102193 0.83 GCG (0.46) GCGADCY6ADCY3ADCY9ADCY5
SCHEMBL3095604 0.83 GCG (0.46) MEN1KMT2AL3MBTL1GCGALDH1A1
SCHEMBL3110137 0.82 MEN1 (0.43) MEN1KMT2AL3MBTL1GCGALDH1A1
SCHEMBL3109979 0.82 GCG (0.43) MEN1KMT2AL3MBTL1GCGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR MEN1 233/4885KMT2A 2159/4885L3MBTL1 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.